A translational research team led by the National University of Singapore (NUS) has harnessed CURATE.AI, a powerful artificial intelligence platform, to successfully treat a patient with advanced cancer, completely halting disease progression, said a statement on Friday.
According to the official statement released by NSU, in this clinical study, a patient with metastatic castration-resistant prostate cancer (MCRPC) was given a novel drug combination consisting of investigational drug ZEN-3694 and enzalutamide, an approved prostate cancer drug. The research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.
With this achievement, the CURATE.AI team now expects to broadly deploy the platform for the prevention of transplant rejection, adult and paediatric cancers, cardiovascular medicine, diabetes management, infectious diseases, and many other applications.
Professor Dean Ho, Director of the Singapore Institute for Neurotechnology (SINAPSE) at NUS, who led the study, said in the statement, “Dynamic dosing in cancer therapy is not commonly used. In fact, drug dosing changes in oncology are typically performed only to reduce toxicity. CURATE.AI uniquely modifies drug dosing to increase efficacy. Our clinical study has shown that dosing can profoundly affect the efficacy and safety of the treatment. A patient’s clinical profile changes over time. The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimised personalised medicine.”
Combination Therapy
Using the combination therapy approach, multiple drugs are used to attack the processes that support cancer growth. A primary objective when designing combination therapies is to achieve drug synergy, where the drugs work together to substantially improve efficacy. While combination therapy has generally improved treatment outcomes such as overall survival for many cancers, it is predominantly given at both fixed as well as high doses.
Harnessing AI To Optimise Combination Therapy
To overcome the challenges of conventional combination therapy, the NUS team developed the CURATE.AI platform, which uses the patient’s own clinical data — such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood — to calibrate her/his unique response to treatment. This calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.
“No two patients’ profiles are alike, and as a patient’s body and cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an unprecedented advance for combination therapy,” Prof Ho explained.
More Clinical Trials
CURATE.AI is applicable to all diseases and all patients, and a first generation of the platform was previously validated in the clinic for single drug optimisation in post-transplant immunosuppression. This new study demonstrates that CURATE.AI can optimise multi-drug regimens.
Multiple clinical trials using CURATE.AI-guided combination therapy for oncology and additional applications such as post-transplant immunosuppression are underway. In addition, patient recruitment for additional oncology trials in Singapore has been approved.
Archive
- October 2024(19)
- September 2024(94)
- August 2024(100)
- July 2024(99)
- June 2024(126)
- May 2024(155)
- April 2024(123)
- March 2024(112)
- February 2024(109)
- January 2024(95)
- December 2023(56)
- November 2023(86)
- October 2023(97)
- September 2023(89)
- August 2023(101)
- July 2023(104)
- June 2023(113)
- May 2023(103)
- April 2023(93)
- March 2023(129)
- February 2023(77)
- January 2023(91)
- December 2022(90)
- November 2022(125)
- October 2022(117)
- September 2022(137)
- August 2022(119)
- July 2022(99)
- June 2022(128)
- May 2022(112)
- April 2022(108)
- March 2022(121)
- February 2022(93)
- January 2022(110)
- December 2021(92)
- November 2021(107)
- October 2021(101)
- September 2021(81)
- August 2021(74)
- July 2021(78)
- June 2021(92)
- May 2021(67)
- April 2021(79)
- March 2021(79)
- February 2021(58)
- January 2021(55)
- December 2020(56)
- November 2020(59)
- October 2020(78)
- September 2020(72)
- August 2020(64)
- July 2020(71)
- June 2020(74)
- May 2020(50)
- April 2020(71)
- March 2020(71)
- February 2020(58)
- January 2020(62)
- December 2019(57)
- November 2019(64)
- October 2019(25)
- September 2019(24)
- August 2019(14)
- July 2019(23)
- June 2019(54)
- May 2019(82)
- April 2019(76)
- March 2019(71)
- February 2019(67)
- January 2019(75)
- December 2018(44)
- November 2018(47)
- October 2018(74)
- September 2018(54)
- August 2018(61)
- July 2018(72)
- June 2018(62)
- May 2018(62)
- April 2018(73)
- March 2018(76)
- February 2018(8)
- January 2018(7)
- December 2017(6)
- November 2017(8)
- October 2017(3)
- September 2017(4)
- August 2017(4)
- July 2017(2)
- June 2017(5)
- May 2017(6)
- April 2017(11)
- March 2017(8)
- February 2017(16)
- January 2017(10)
- December 2016(12)
- November 2016(20)
- October 2016(7)
- September 2016(102)
- August 2016(168)
- July 2016(141)
- June 2016(149)
- May 2016(117)
- April 2016(59)
- March 2016(85)
- February 2016(153)
- December 2015(150)